These analyses indicate that the status of ABCB1 gene expression has a larger impact on patients with ovarian cancer resistant to platinum drugs than on platinum drug-sensitive patients; in drug-resistant patients, a stronger correlation was observed in patients who retained p53null mutations than in those groups with missense mutations in the TP53 gene. Here, ABCB1 is linked to ovarian cancer.